CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biocardia Lifesciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biocardia Lifesciences Inc
125 Shoreway Rd
Suite B
Phone: (650) 226-0120p:650 226-0120 San Carlos, CA  94070-2718  United States Fax: (302) 655-5049f:302 655-5049

BioCardia, Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-205003 ) with the SEC on 4/15/2016. The Company is seeking withdrawal of the Registration Statement because of unfavorable market conditions.

Business Summary
Biocardia Lifesciences Inc, foemerly BioCardia, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutics for cardiovascular diseases. It develops therapeutic candidates, with a focus on heart failure resulting from a heart attack, such as CardiAMP Cell Therapy System (CardiAMP), an autologous minimally processed bone marrow cells from a patient's own cells, and CardiALLO Cell Therapy System (CardiALLO), an allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients. Its CardiAMP cell processing platform processes bone marrow aspirate at the point of care to concentrate mononuclear cells and prepare the dosage form. Its product lines include the Helix biotherapeutic delivery system that offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart, as well as the Morph vascular access product line.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201512/31/2014YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Simon H.Stertzer 83 1/1/2002 1/1/2002
President, Chief Executive Officer, Director PeterAltman 53 1/1/2002 1/1/2002
Chief Financial Officer Gary S.Titus 59 5/1/2014 5/1/2014
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 30 (As of 3/31/2015)
Outstanding Shares: 11,205,830 (As of 7/15/2015)
Stock Exchange: NASD
Federal Tax Id: 470892881
Fax Number: (302) 655-5049
Email Address: info@biocardia.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023